S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Mereo BioPharma Group Stock Forecast, Price & News

+0.12 (+8.51%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
7.91 million shs
Average Volume
11.87 million shs
Market Capitalization
$178.98 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive MREO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter.

MREO Stock Forecast (MarketRank)

Overall MarketRank

1.98 out of 5 stars

Medical Sector

617th out of 1,411 stocks

Pharmaceutical Preparations Industry

285th out of 672 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Mereo BioPharma Group logo

About Mereo BioPharma Group (NASDAQ:MREO)

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

MREO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Pretax Margin


Sales & Book Value

Annual Sales
$50.14 million
Cash Flow
$0.16 per share
Book Value
$1.03 per share


Free Float
Market Cap
$178.98 million
Not Optionable

Mereo BioPharma Group Frequently Asked Questions

Should I buy or sell Mereo BioPharma Group stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mereo BioPharma Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Mereo BioPharma Group stock.
View analyst ratings for Mereo BioPharma Group
or view top-rated stocks.

What is Mereo BioPharma Group's stock price forecast for 2022?

3 equities research analysts have issued 1 year price targets for Mereo BioPharma Group's shares. Their MREO stock forecasts range from $5.00 to $8.00. On average, they predict Mereo BioPharma Group's share price to reach $7.00 in the next year. This suggests a possible upside of 357.5% from the stock's current price.
View analysts' price targets for Mereo BioPharma Group
or view top-rated stocks among Wall Street analysts.

How has Mereo BioPharma Group's stock performed in 2022?

Mereo BioPharma Group's stock was trading at $1.60 at the beginning of the year. Since then, MREO shares have decreased by 4.4% and is now trading at $1.53.
View the best growth stocks for 2022 here

When is Mereo BioPharma Group's next earnings date?

Mereo BioPharma Group is scheduled to release its next quarterly earnings announcement on Thursday, June 30th 2022.
View our earnings forecast for Mereo BioPharma Group

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the following people:
  • Dr. Denise Scots-Knight Ph.D., Co-Founder, CEO & Exec. Director (Age 63, Pay $880.7k)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 53)
  • Dr. Alastair MacKinnon M.D., MBBS, Co-Founder and Chief of Portfolio & Pipeline Strategy (Age 52)
  • Dr. John P. Richard M.B.A., MBA, Co-Founder & Chief Bus. Officer (Age 65)
  • Ms. Christine Fox CPA, Chief Financial Officer (Age 41)
  • Dr. John A. Lewicki Ph.D., Chief Scientific Officer (Age 70)
  • Dr. Jackie Parkin, Therapy Area Head of Respiratory Endocrinology
  • Ms. Alexandra Hughes-Wilson, Chief of Patient Access & Commercial Planning (Age 51)
  • Dr. Suba Krishnan, Sr. VP of Clinical Devel.
  • Dr. Fiona Bor, Head of Intellectual Property

What other stocks do shareholders of Mereo BioPharma Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mereo BioPharma Group investors own include VBI Vaccines (VBIV), Pfizer (PFE), Otonomy (OTIC), OpGen (OPGN), OPKO Health (OPK), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Vaxart (VXRT), Aduro Biotech (ADRO) and Affimed (afmd).

When did Mereo BioPharma Group IPO?

(MREO) raised $49 million in an initial public offering (IPO) on the week of April 23rd 2018. The company issued 2,800,000 shares at a price of $17.62 per share. Cowen, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Cantor Fitzgerald Europe were co-managers.

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the NASDAQ under the ticker symbol "MREO."

Who are Mereo BioPharma Group's major shareholders?

Mereo BioPharma Group's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rock Springs Capital Management LP (5.19%), Clearline Capital LP (1.11%), BlackRock Inc. (0.64%), Maven Securities LTD (0.47%), Eversept Partners LP (0.32%) and Renaissance Technologies LLC (0.24%).

Which major investors are selling Mereo BioPharma Group stock?

MREO stock was sold by a variety of institutional investors in the last quarter, including Simplex Trading LLC.

Which major investors are buying Mereo BioPharma Group stock?

MREO stock was bought by a variety of institutional investors in the last quarter, including Clearline Capital LP, Rock Springs Capital Management LP, BlackRock Inc., Maven Securities LTD, J. Goldman & Co LP, Bank of America Corp DE, Eversept Partners LP, and Renaissance Technologies LLC.

How do I buy shares of Mereo BioPharma Group?

Shares of MREO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mereo BioPharma Group's stock price today?

One share of MREO stock can currently be purchased for approximately $1.53.

How much money does Mereo BioPharma Group make?

Mereo BioPharma Group (NASDAQ:MREO) has a market capitalization of $178.98 million and generates $50.14 million in revenue each year.

How many employees does Mereo BioPharma Group have?

Mereo BioPharma Group employs 38 workers across the globe.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. The official website for Mereo BioPharma Group is www.mereobiopharma.com. The company can be reached via phone at 44-33-3023-7300 or via email at [email protected].

This page (NASDAQ:MREO) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.